Fintel reports that on April 22, 2025, William Blair downgraded their outlook for Medpace Holdings (NasdaqGS:MEDP) from ...

Fintel reports that on April 21, 2025, William Blair initiated coverage of Zillow Group (NasdaqGS:ZG) with a Market Perform ...

Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a keenly ...

William Blair initiated coverage of Xencor (XNCR) with an Outperform rating. The firm believes the biopharmaceutical industry is entering a ...

William Blair initiated coverage of Zillow Group with a Market Perform rating. Zillow is the clear leader among home search portals in visitor traffic, with first-mover advantages ...

William Blair Small Cap Growth Fund earns an Average Process Pillar rating. The main contributor to the rating is the fund's excellent long-term risk-adjusted performance. This can be seen in its ...

William Blair analyst T. Romeo now anticipates that the company will post earnings per share of $0.21 for the quarter, down from their previous estimate of $0.26.

Popular Western medicines for diseases including cancer and diabetes have been caught in the escalating U.S.-China trade war, ...

Viking Therapeutics enjoyed a nice share rally on the news that rival Pfizer is discontinuing obesity candidate danuglipron.